BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF-mutated tumors are reviewed.
Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia.
Svetlana A
SA
Protsenko
Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia.
Anna I
AI
Semionova
Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia.
Yuri I
YI
Komarov
Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia.
Svetlana N
SN
Aleksakhina
Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia.
Alexandr O
AO
Ivantsov
St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia.
Aglaya G
AG
Iyevleva
Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia. evgeny@imyanitov.spb.ru.|St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia. evgeny@imyanitov.spb.ru.|I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia. evgeny@imyanitov.spb.ru.|St. Petersburg State University, St. Petersburg, 199034, Russia. evgeny@imyanitov.spb.ru.
Evgeny N
EN
Imyanitov
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D018227:Sarcoma, Clear Cell / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf
BRAF; Clear cell sarcoma; Review; Vemurafenib